News Quantified

IMAB – i-mab - american depositary shares (US:NASDAQ)

Everest Medicines Acquires Exclusive Greater China and Other Asian Country Rights to VIS-101, a Novel Bifunctional Biologic for Serious Eye Disorders

10/29

11:15 am

imab

Low

I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMAB

I-Mab (NASDAQ:IMAB) had its "buy" rating reaffirmed by analysts at Citigroup Inc..

I-Mab (NASDAQ:IMAB) had its "buy" rating reaffirmed by analysts at HC Wainwright.

Live Event: Join our next subscriber-only event: "The Data Driven Investor"

Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}